Author

TM Mark

Observed name: T. M. Mark

Institution: University of Colorado Anschutz

Observed institution: University of Colorado Anschutz

OpenAlex ID: A5087861779

P04: Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone in Patients With Previously Treated Multiple Myeloma: Overall Survival Results From the Phase 3 Castor Trial

2022 · P Sonneveld, A Chanan-Khan, et al. · HemaSphere · 7

An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.

2010 · T. M. Mark, A. Koirala, et al. · Journal of Clinical Oncology · 1

A610 T-BiRD Therapy for Up-Front Use in Symptomatic Multiple Myeloma

2009 · TM Mark, M Coleman, et al. · Clinical Lymphoma & Myeloma

A609 Extended Follow-up Results of BiRD Therapy: Prolonged Responses Achieved

2009 · TM Mark, M Coleman, et al. · Clinical Lymphoma & Myeloma

Works count: 4

Citation count: 8

H-index: 1

I10-index: